When Ebola began to spread around the globe last year, there was disbelief that there were no treatments available. Inevitably people wanted to know, “Why is it so difficult and why does it take so long?” As the chairman of vaccines for the pharmaceutical company GlaxoSmithKline (GSK), Moncef Slaoui is used to hearing those questions. Moncef first started working on a vaccine for malaria 30 years ago and GSK has invested more than $500 million to develop it. Late last year, GSK began working on an Ebola vaccine and its development is being accelerated due in part to the lessons learned from malaria.

What goes into the research and development of novel medicines and what does the future hold? What bad bugs and infections are going to emerge next and how do we prepare for them? What is the industry working on now that is going to be transformative ten years from now?

Join Moncef for a discussion on innovation in medicines and vaccines development.

TUESDAY, SEPTEMBER 15, 2015 • 5:00 P.M.
MASTERS 110, MARA AUDITORIUM

This seminar program is supported by a grant to Gettysburg College from the Howard Hughes Medical Institute through the Precollege and Undergraduate Science Education Program.